Global Musculoskeletal Partnering 2016-2023: Deal trends, players and financials
Global Musculoskeletal Partnering 2016-2023: Deal trends, players and financials provides comprehensive understanding and unprecedented access to the musculoskeletal partnering deals and agreements entered into by the worlds leading healthcare companies.
Global Musculoskeletal Partnering 2016 to 2023 provides the full collection of musculoskeletal disease deals signed between the world’s pharmaceutical and biotechnology companies since 2016.
- Trends in musculoskeletal partnering deals
- Financial deal terms for headline, upfront and royalty by stage of development
- Musculoskeletal partnering agreement structure
- Musculoskeletal partnering contract documents
- Top musculoskeletal deals by value
- Most active musculoskeletal dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive musculoskeletal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Musculoskeletal deals.
The report presents financial deal terms values for musculoskeletal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of musculoskeletal dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in musculoskeletal dealmaking since 2016 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading musculoskeletal deals since 2016. Deals are listed by headline value. The chapter includes the top 25 most active musculoskeletal dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to musculoskeletal deals since 2016 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all musculoskeletal partnering deals by specific musculoskeletal target announced since 2016. The chapter is organized by specific musculoskeletal therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all musculoskeletal partnering deals signed and announced since 2016. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in musculoskeletal partnering and dealmaking since 2016.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of musculoskeletal technologies and products.
Global Musculoskeletal Partnering 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to musculoskeletal trends and structure of deals entered into by leading companies worldwide.
Global Musculoskeletal Partnering 2016 to 2023 includes:
- Trends in musculoskeletal dealmaking in the biopharma industry since 2016
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of musculoskeletal deal contract documents
- Comprehensive access to over 600 musculoskeletal deal records
- The leading musculoskeletal deals by value since 2016
- Most active musculoskeletal dealmakers since 2016
The report includes deals for the following indications: Arthritis, Ankylosing spondylitis, Juvenile arthritis, Osteoarthritis, Psoriatic arthriti, Rheumatoid arthritis, Bone fracture, Hip, Carpel tunnel syndrome, Frozen shoulder, Gout, Knee, Meniscus damage, Muscular dystrophy, Osteoporosis, Paget's disease, Spinal muscular atrophy, Bone pain, Back pain, Muscular pain, Stiffness, Weakness, plus other musculoskeletal indications.
In Global Musculoskeletal Partnering 2016 to 2023, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Musculoskeletal Partnering 2016-2023 report provides comprehensive access to available deals and contract documents for over 600 musculoskeletal deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are the sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Global Musculoskeletal Partnering 2016 to 2020 provides the reader with the following key benefits:
- In-depth understanding of musculoskeletal deal trends since 2016
- Access musculoskeletal deal headline, upfront, milestone and royalty data
- Research hundreds of actual contracts between musculoskeletal partner companies
- Comprehensive access to over 600 links to actual musculoskeletal deals entered into by the world’s biopharma companies
- Indepth review of musculoskeletal deals entered into by the top 25 most active dealmakers
- Benchmark the key deal terms companies have agreed in previous deals
- Identify key terms under which companies partner musculoskeletal opportunities
- Uncover companies actively partnering musculoskeletal opportunities
Chapter 1 – Introduction
Chapter 2 – Trends in musculoskeletal dealmaking
2.2. Musculoskeletal partnering over the years
2.3. Musculoskeletal partnering by deal type
2.4. Musculoskeletal partnering by industry sector
2.5. Musculoskeletal partnering by stage of development
2.6. Musculoskeletal partnering by technology type
2.7. Musculoskeletal partnering by therapeutic indication
Chapter 3 –Financial deal terms for musculoskeletal partnering
3.2. Disclosed financials terms for musculoskeletal partnering
3.3. Musculoskeletal partnering headline values
3.4. Musculoskeletal deal upfront payments
3.5. Musculoskeletal deal milestone payments
3.6. Musculoskeletal royalty rates
Chapter 4 – Leading musculoskeletal deals and dealmakers
4.2. Most active in musculoskeletal partnering
4.3. List of most active dealmakers in musculoskeletal
4.4. Top musculoskeletal deals by value
Chapter 5 – Musculoskeletal contract document directory
5.2. Musculoskeletal partnering deals where contract document available
Chapter 6 – Musculoskeletal dealmaking by therapeutic target
6.2. Deals by musculoskeletal therapeutic target
Appendix 1 – Directory of musculoskeletal deals by company A-Z since 2016
Appendix 2 – Directory of musculoskeletal deals by deal type since 2016
Appendix 3 – Directory of musculoskeletal deals by stage of development since 2016
Appendix 4 – Directory of musculoskeletal deals by technology type since 2016
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Recent report titles from CurrentPartnering
Table of figures
Figure 1: Musculoskeletal partnering since 2016
Figure 2: Musculoskeletal partnering by deal type since 2016
Figure 3: Musculoskeletal partnering by industry sector since 2016
Figure 4: Musculoskeletal partnering by stage of development since 2016
Figure 5: Musculoskeletal partnering by technology type since 2016
Figure 6: Musculoskeletal partnering by indication since 2016
Figure 7: Musculoskeletal deals with a headline value
Figure 8: Musculoskeletal deals with upfront payment values
Figure 9: Musculoskeletal deals with milestone payment
Figure 10: Musculoskeletal deals with royalty rates
Figure 11: Active musculoskeletal dealmaking activity since 2016
Figure 12: Top musculoskeletal deals by value since 2016
*For the full list of companies mentioned in the report, please contact email@example.com
- $3,995: single-user
- $5,745: multi-user
- $10,995: single site license
- $17,995: global site license
A full explanation of license type definitions can be found here.
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
All card payments are processed by SagePay.
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
3D-Side, 3SBio, 4P-Pharma, 4P Therapeutics, A2A Pharmaceuticals, Aavis Pharmaceuticals, Abarca, Abbvie, AbCellera Biologics, Academy Medical, AC Bioscience, Accenture, Aceragen, Aclarion, Activbody, Active Implants, Adaptive Health, Additive Orthopaedics, Advanced Human Imaging, AdventHealth, Affinia Therapeutics, AGC Asahi Glass, Ageless Biotech, AgNovos Healthcare, AgomAb Therapeutics, Akashi Therapeutics, AKL Research and Development, Alcyone Therapeutics, AlfaMed, Aligos Therapeutics, AliMed, Alkem Laboratories, Allay Therapeutics, Allergan, AlloSource, Almirall, Alpine Immune Sciences, Altasciences, Alvogen, Alvotech, Ambry Genetics, Amend Surgical, American Association of Neuromuscular & Electrodiagnostic Medicine, Amgen, Amneal Pharmaceuticals, AMRA, AMRA Medical, Anagenesis Biotechnologies, AnaMar, Angelini Pharma, Angers University, Anika Therapeutics, AnnJi Pharmaceutical, Antares Pharma, Antibe Therapeutics, Apple, Apsen Farmacutica, Aptahem, Aptorum Group, Aralez Pharmaceuticals, Aratana Therapeutics, Aravive Biologics, Arctic Therapeutics, argenx, ARK Crystal, Arrowhead Pharmaceuticals, Arthrex, Arthrosi Therapeutics, Artialis, Asahi Kasei, Ascendis Pharma, AskAt, Asklepios Biopharmaceutical, Assertio Therapeutics, Astellas Pharma, AstraZeneca, Athrotech, Atnahs Pharma, Audentes Therapeutics, Aurinia Pharmaceuticals, Autotelic BIO, Avalere Health, Avanos Medical, Avenue Therapeutics, Aveta Biomics, AveXis, Avidity Biosciences, Avion Pharmaceuticals, AWB Schraubtechnik und Industriebedarf, Axelys, Axovant Gene Therapies, Aziyo Biologics, Back-A-Line, Baebies, Bamboo Therapeutics, Bauerfeind, Baxalta, Bayer, Baylor College of Medicine, Bazis NN, BC Platforms, Beijing Tide Pharmaceutical, Benitec Biopharma, Berg, BGI, BillionToOne, BinnoPharm, Bio-Thera Solutions, BioAge Labs, BioCanRx, Biocomposites, Biogen, BioGen Medical, Biohaven Pharmaceuticals, BioInvent, Biologica Technologies, BioMarin Pharmaceutical, BioMed X Innovation Center, Bioqube Ventures, BioRestorative Therapies, BioSenic, Bioservo Technologies, Biosolution, Biosplice, Bioventus, BioVinc, Bison & Rose, Blueprint Medicines, Bodycad, Boehringer Ingelheim, Bone Biologics, Bone Therapeutics, Brain Canada, Brickell Biotech, Brigham and Women's Hospital, Bristol-Myers Squibb, BRM Extremities, Broad Institute, Burke Therapeutics, c-LEcta, Caerus Strength, California Institute for Regenerative Medicine, Calimmune, Calliditas Therapeutics, Camargo Pharmaceutical Services, Camber Spine Technologies, Can-Fite BioPharma, CANbridge Pharmaceuticals, Cantargia, Capricor Therapeutics, Capsigen, CareFirst BlueCross BlueShield, Carlsmed, Carmell Therapeutics, Carna BioSciences, CartiHeal, Cartiva, CAS, Casper Pharma, Cassie + Friends, Catabasis Pharmaceuticals, Catalent, Catalyst Pharmaceuticals, cbdMD, Cedars-Sinai Medical Center, Celgene, Celltech, Cellthera Pharma, Celltrion, Cellular Biomedicine, Cel Sci, Centinel Spine, Centogene, Cerhum, CgBio, Changshan Pharm, Charles River Laboratories, CheckPoint Immunology, Children's Hospital Boston, Children's Hospital of Philadelphia, Children's Research Institute, Chronolife, Chugai Pharmaceutical, CHU Sainte-Justine, Cigna Healthcare, Cipla, CJ CheilJedang, Clementia Pharmaceuticals, Clinical Graphics, CMS Medical, Coapt, Cocoon Biotech, Codiak BioSciences, Coeptis Pharmaceuticals, Coherus Biosciences, Collaborative Trajectory Analysis Project, College Park Industries, Collplant, Colorado State University, Columbia University, Columbia University Medical Center, ConforMIS, Consortium AI, Control Bionics, Conventus Orthopaedics, Coracoid Solutions, Corin, Cortexyme, CRISPR Therapeutics, CrystalGenomics, CSIR-Central Drug Research Institute, CSPC Pharmaceutical Group, Cumberland Pharmaceuticals, Curasan, Cure Duchenne, CURE Pharmaceutical, CurveBeam AI, CymaBay Therapeutics, Cytoo, Cyxone, Daewoong Pharmaceutical, Daiichi Sankyo, Dalhousie University, Defense Advanced Research Projects Agency, Delivra, Delpor, Denali Therapeutics, Department of Defense, Department of Veterans Affairs, DePuy, Desma HC, Distributed Bio, DJO Surgical, DJS Antibodies, DMD Therapeutics, Duchenne UK, Duke University, DuraStat, Dynacure, Dyne Therapeutics, Dyno Therapeutics, Echolight Medical, ECM Therapeutics, Ecole Polytechnique de Montreal, EGeen, Eisai, Elanco, Eli Lilly, Ellipse Technologies, Eluthia, Ember Therapeutics, Embryo Ventures, EmergeOrtho, Emmyon, Emory University, Emovi, Endo International, Endo Ventures, Energy Medicine Research Institute, Engage Surgical, Enleofen Bio, Entrada Therapeutics, Enzene Biosciences, Equillium, Ethos Research & Development, Ethypharm, Eurofins LifeCodexx, Europe Technologies, Eversana, Evonik Industries, EVOQ Therapeutics, Ewopharma, Exactech, Exagen Diagnostics, ExCEEd Orphan, Exicure, Exonics Therapeutics, Exothera, Facio Therapies, Feinstein Institute for Medical Research, Ferring Pharmaceuticals, Fibrocell Science, Fidelta, Fin-ceramica faenza spa, Flexion Therapeutics, Fluidigm, Food and Drug Administration (FDA), Forbius, Forge Biologics, Frequency Therapeutics, Fresenius Kabi Pharmaceuticals, Friends of FSH Research, FSHD Global Research Foundation, Fujifilm Kyowa Kirin Biologics, Fuji Yakuhin, Fulcrum Therapeutics, Fuse Medical, G3 Therapeutics, Galapagos, Galderma, Galecto, Galvani Bioelectronics, Gebro Pharma, Geisinger Health System, Geistlich Pharma, GEn1E Lifesciences, Genascence, GenEdit, GeneQuine Biotherapeutics, General Electric (GE), Genethon, Geneva Foundation, Genevant Sciences, Genkyotex, Gennao Bio, Genome BC, Genome Canada, Genticel, George Washington University, Gero, GetHealthy, Gilead Sciences, GlaxoSmithKline, Globus Medical, Graminex, Graviton Bioscience, Gravocore, Great Ormond Street Hospital (GOSH), Grunenthal, Guangzhou Ruianbo Pharmaceutical Technology, Guangzhou Ruiao Biopharmaceutical Technology, Hackensack University Medical Center, Haisco Pharmaceutical, HanAll Pharmaceuticals, Hansa Biopharma, Hanuman Pelican, HappyBond, Harbour Biomed, Harmonic Bionics, Harvard University, HAYA Therapeutics, Health2Work, Healthcare Royalty Partners, HealthSnap, HealthTrio, Healthy Directions, HemoShear, Henlius Biotech, High Line Bio, Hikma Pharmaceuticals, HistoIndex, Hoffmann La Roche, Horizon Europe, Horizon Pharma plc, Horizon Therapeutics, Hospital for Special Surgery, H Robotics, Human Life CORD Japan, I-mab, Idera Pharmaceuticals, IDIPharma, Idorsia, IGEA Clinical Biophysics, Iktos, IM-Tech, Image Analysis, ImageBiopsy Lab, IMASCAP, Imcyse, Immunis, Impressio, In2Bones USA, Incyte, Indiana University, Innosuisse, Innosurge, Innovate UK, Innovent Biologics, Innovus Pharmaceuticals, Inovalon, Inserm, Insilico Biotechnology, Integra LifeSciences, Integrated Biosciences, Integrum, Intel, International Spine Study Group Foundation, IntraFuse, Intrexon, Inventiva, Invibio Biomaterial Solutions, Invitae, Ionis Pharmaceuticals, Ipsen, IQVIA, Ironwood Pharmaceuticals, Italfarmaco, IthenaPharma, Iturri, Izana Bioscience, Jain Foundation, Janssen Pharmaceuticals, Janssen Research & Development, Japan Medical Dynamic Marketing, Jesse's Journey, Jiangsu Aosaikang Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Jiangsu Tainuo, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, Jointpoint, Jounce Therapeutics, Jubilant Pharma, Jubilant Radiopharma, Jubilant Therapeutics, Juniper Biologics, Juvena Therapeutics, Juvenescence, Juvenomics, JW Pharmaceutical, Kalytera Therapeutics, Kansas State University, Karolinska Institute, Kashiv BioSciences, Kawasaki Medical School, Keck School of Medicine of USC, Kelyniam Global, Kennedy Institute of Rheumatology, KFx Medical, Kiniksa Pharmaceuticals, KiOmed Pharma, Kitov Pharma, Kolon Life Science, Konica Minolta, Kowa Pharmaceuticals America, Kuhnil Pharmaceuticals, Kuros Biosciences, KYE Pharmaceuticals, Kyocera, Kyowa Hakko Kirin, Laboratories Acbel, LABORATORIOS SAVAL, Laboratory Corporation of America, Landos Biopharma, Laurel Venture Capital, Leadiant Biosciences, Les Laboratoires Servier, Level Brands, Lexicon Pharmaceuticals, LG Chem, Lifehealthcare, Lima Corporate, Link Health, LNE/G-Med, Locana, London School of Medicine and Dentistry, Lonza, Ludwig Institute for Cancer Research, Lumicera Health Services, Lupin, Lynk Pharmaceuticals, Maastricht University, Mabwell Bioscience, MainPointe, Marathon Pharmaceuticals, Marina Biotech, Maryland Stem Cell Research Fund, Massachusetts General Hospital, Massachusetts Institute of Technology, Mathys Medical, Maxiim, Maxx Medical, Mayo Clinic, MC10, McMaster University, MDA Venture Philanthropy, Medac, Medacta, Medexus Pharmaceuticals, Mediar Therapeutics, Medical Enterprises Distribution, Medicardia Health, Medidata Solutions, MedImmune, Medolife Rx, Medosome Biotec, Medovex, MedRhythms, Medservice, MedShape, Medtronic, Merck and Co, Merck KGaA, Mesoblast, Metabolon, Methuselah Foundation, Metrion Biosciences, MHC Medical Products, Microdrop, MicroPort Orthopedics, MiMedx, Miravo Healthcare, miRecule, Mithra Pharmaceuticals, Mitsubishi Tanabe Pharma, Moberg Pharma, Modernizing Medicine, Moebius Medical, Momenta Pharmaceuticals, MoonLake Immunotherapeutics, Morphic Therapeutic, MorphoSys, Morris Animal Foundation, Motorika, MoveUP, mSKIL, MTF Biologics, Mundipharma, Muscle Activation Technique, Muscular Dystrophy Association, Musculoskeletal Transplant Foundation, Mylan Laboratories, Mylan Pharmaceuticals, Myomo, Myonexus Therapeutics, MYOS, Myosana Therapeutics, Myriad Genetics, myTomorrows, Nanotherapeutics, National Human Genome Research Institute, National Institute of Arthritis and Musculoskeletal Diseases, National Institute on Aging, National Institutes of Health, National Science Foundation, Nationwide Children’s Hospital, Navidea Biopharmaceuticals, Navitas, NEMO Health, NeoDynamics, Nestle, Neuro42, Neurocrine Biosciences, NeuroMuscular Orthotics, Neuronoff, NeuroVive Pharmaceutical, NeuX Technologies, Nextremity Solutions, NImmune Biopharma, Nippon Shinyaku, Nordic Bioscience, Nordic Pharma Group, Northway Biotechpharma, Northwell Health, Northwestern University, NovaQuest, Novara Therapeutics, Novartis, Novosteo, NT Pharma, Nuevolution, Numotion, Nuritas, NuVasive, Nuvo Research, nView Medical, Ohio State Innovation Foundation, Ohio State University, OncoArendi Therapeutics, Oncodesign, Onkos Surgical, Ono Pharmaceutical, Open University of Israel, OPUM, Orebro University, Organon, Organovo, Origo Biopharma, Orsini Healthcare Specialty Pharmacy, Orthocell, Orthofix Medical, OrthogenRx, OrthoGrid Systems, OrthoGrow, Orthopaedic Foot & Ankle Center, Orthopaedic Research UK, Ortho Regenerative Technologies, OrthoSensor, Ortho Transmission, Ortoma, OSSIS, Ossur, Osteolabs, Osteopore International, Oxford Biomedica Solutions, OxyPharma, Pacira Biosciences, Padlock Therapeutics, Paladin Labs, Paragon 28, ParcelShield, Parent Project Muscular Dystrophy, Parvizi Surgical Innovation, Patheon, Patient-Centered Outcomes Research Institute, PDL BioPharma, Pennsylvania State University, PeptiDream, Pfenex, Pfizer, Pfizer Japan, PharmaLegacy Laboratories, PharmaLynk, Pharmapark, Physimax Technologies, Piramal Healthcare, Pixee Medical, Pluristem Therapeutics, Poietis, Polypeptide Laboratory, Precision BioSciences, Pregene Biopharma, Premier Inc, Prime Therapeutics, PrinterPrezz, Promedior, Prometheus Laboratories, Promimic, Propella Therapeutics, Provider Network of America, PTC Therapeutics, pt Health, Purdue Pharma, Purdue Research Foundation, Quanta, QuantHealth, Queen Mary University of London, Quinn Medical, Radius Health, Rainbow Medical, Ramot at Tel Aviv University, Rebel Edibles, Recombinetics, Recursion, Redx Pharma, Regen BioPharma, Regeneron Pharmaceuticals, Regeneus, RegenLab, Regenstrief Institute, Regenxbio, Rehabtronics, Remedium Bio, Renovis, Replicel Life Sciences, Resonant Specific Technologies, Responsive Orthopedics, RevBio, ReveraGen BioPharma, Revolo Biotherapeutics, Rheumatology Research Foundation, Rhino Assembly, Ribon Therapeutics, Rigenerand, Riptide Bioscience, RMX Biopharma, Roche, Rocket Pharmaceuticals, ROMEG Therapeutics, Royalty Pharma, Saint Louis University, SAMIL Pharm, Samsung Bioepis, Sanford Burnham Institute, Sangamo Therapeutics, Sanguine, Sanofi, Santhera Pharmaceuticals, Saol Therapeutics, Saphetor, Sarepta Therapeutics, Satellos Bioscience, SAVSU Technologies, Sayre Therapeutics, Science Biotech, Scipher Medicine, Scripps Research Institute, Scriptr Global, Second Genome, SecondWave Systems, Seikagaku, Selecta Biosciences, Selvita, Serenus.AI, Shionogi, Shire Pharmaceuticals, Si-Bone, Sierra Oncology, Simcere Pharmaceuticals, SimonMed Imaging, SiSaf, Sites Medical, SIT Laboratorio Farmaceutico, Skyhawk Therapeutics, Smith & Nephew, Sofregen Medical, Solid Biosciences, SomaLogic, Sorrento Therapeutics, Southwest Research Institute, Southwest Transplant Alliance, SpineThera, Spotlight Innovation, SQI Diagnostics, Standigm, Steeper Group, Stempeutics, Storm ID, StrideBio, Strides Arcolab, StrongPath, Stryker, Summit Therapeutics, Sun Pharmaceutical, Surgalign, SurGenTec, Surgical Planning Associates, Surgical Specialties, Sway Medical, Swedish Bactiguard, Swedish Orphan Biovitrum, SWK Funding, SynAct Pharma, Synpromics, Syntr Health Technologies, Taiwan Liposome Company, Takeda Pharmaceutical, Technology Consult Berlin, Teijin, Tenex Health, Teva Pharmaceutical Industries, Tevard Biosciences, Texas Christian University, The Arthritis Society, The Cyprus Institute of Neurology and Genetics, Theramex, THINK Surgical, Thuasne and Townsend Design, TissueGene, Tissue Genesis, Tissue Regenix, TiumBio, TLC BioSciences, Toshiba Medical Systems Corporation, Total Joint Orthopedics, Touch Bionics, Tow Foundation, TR-Pharm, TracPatch Health, Transcenta, Transdermal Delivery Solutions, TRB Chemedica, TrialSpark, Trice Medical, Tufts University, Turner Imaging Systems, UCB, Ultragenyx Pharmaceuticals, Unilife, United Orthopedic Group, University City Science Center, University of Basel, University of Bern, University of British Columbia, University of California, San Diego (UCSD) School of Medicine, University of California Berkeley, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Edinburgh, University of Florida, University of Illinois, University of Illinois Urbana-Champaign, University of Iowa, University of Kansas, University of Lausanne, University of Liverpool, University of L’Aquila, University of Maryland Baltimore, University of Massachusetts Medical School, University of Miami, University of Michigan, University of Minnesota, University of Missouri, University of Ottowa, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Rochester, University of Sydney, University of Texas, University of Texas Southwestern Medical Center, University of Vermont, University of Verona, University of Virginia, University of Washington, University of Western Australia, Urica Therapeutics, US Army, V ClinBio, Verily, VeriSIM Life, Vertex Pharmaceuticals, Vetter, VIB, Victoria University, Virginia Commonwealth University, Virpax Pharmaceuticals, Viscogliosi Brothers, VISEN Pharmaceuticals, Vitalli Bio, Vivo Capital, Vizient, Voronoi, Voxtur, Voyager Therapeutics, Wake Research Associates, Walloon Region Investment Fund, Weill Cornell Medical College, WellDyne, William Harvey Research Instutute, WishBone Medical, Wittenstein, WorldCare Clinical, Wright Medical, WuXi Biologics, Xlife Sciences, XR Medical Group, Yale University, Yposkesi, Ypsomed, Zebra Medical Vision, Zimmer Biomet, Zoetis
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Collaborative R&D
• Contract service
• Equity purchase
• Joint venture
• Royalty financing
• Spin out
• Sub license
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.